Authors
Latest:
Analyzing Outcomes of Immune Checkpoint Blockade Plus Chemo in SCLCAshish Saxena, MD, explains the outcomes of the addition of immune checkpoint blockade to standard chemotherapy for patients with metastatic small cell lung cancer.
Latest:
The New Algorithm for Second-Line Large B-Cell Lymphoma TreatmentThe diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting.
Latest:
Upfront Nivolumab/Chemo Produces Durable Responses in Urothelial CarcinomaMichiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.
Latest:
Addressing the Mechanism of Action for the AKT Pathway in TNBCRebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
Latest:
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantCareful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Latest:
Breaking New Ground in Synovial Sarcoma: Choy on the FDA Approval of Afami-celIn this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.
Latest:
Bridging Science and Compassion in Cancer CareIn the second episode of Emerging Experts, Hemali Batra-Sharma, MD, discusses her passion for oncology and some of the experiences that have helped to shape her career.
Latest:
Early Detection & the Right Treatment Critical for Prostate CancerJohn E. Sylvester, MD, a radiation oncologist with GenesisCare, reviews the importance of treating prostate cancer at the earliest stage possible.
Latest:
Overcoming Obstacles in Prescribing High-Cost Myeloma TherapiesHamlet Gasoyan, MD, discusses some of the common challenges that oncologists face when getting patients started on more costly oral treatments for multiple myeloma.
Latest:
Expanding Treatment Options in Urothelial Cancer With ADCsScott T. Tagawa, MD, MS, FACP, FASCO, discusses the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.
Latest:
Addressing Dosing Methods With Teclistamab in Multiple MyelomaEmma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial (NCT04722146) and sequencing teclistamab (Tecvayli) in patients with multiple myeloma.
Latest:
Durvalumab After Chemotherapy Helps Manage Toxicities in NSCLC TreatmentChemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.
Latest:
Importance of Patient-Reported Outcomes in the GRIFFIN StudyRebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.
Latest:
Analyzing the ESPAC-5F Trial in Borderline Resectable Pancreatic CancerShubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.
Latest:
Long-Term HERIZON-BTC-01 Data Shows Zanidatamab’s Potential in HER2+ BTCShubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.
Latest:
How Do These Data Apply to Community Oncologists?Explanation of how these data apply to community oncologists.
Latest:
Sequencing Therapies in the First and Second Line for Patients With HCCLipika Goyal, MD, discusses first-line options for patients with patients with hepatocellular carcinoma.
Latest:
Advances in CAR T-Cell Therapy in Hematologic MalignanciesKruti Patel, DO, reviews the advancements, landmark trials, and challenges with CAR T-cell therapy for Cancer Immunotherapy Month.
Latest:
Prioritizing Patient QOL in EGFR-Mutated NSCLC TreatmentJill Feldman discusses the background of the phase 2 COCOON trial in advanced non–small cell lung cancer with EGFR mutations.
Latest:
Key Clinical Insights for the Management of Newly Diagnosed Multiple MyelomaPractical insights for the management of patients with NDMM.
Latest:
Ponatinib Shows Promise in PhALLCON Study for Ph+ ALL TreatmentPonatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI despite long-term data pending.
Latest:
Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCLMatthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Recommendations for Diagnosing and Treating Rare Histiocytic NeoplasmsRonald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.
Latest:
Evolving Management Strategies for Phlebotomy-Dependent Polycythemia Vera: The Path ForwardPanelists discuss how new treatments like rusfertide (a hepcidin mimetic) offer promising options for polycythemia vera patients, demonstrating benefits in reducing phlebotomy requirements while addressing the paradoxical iron deficiency caused by current treatments, potentially improving quality of life while allowing patients to maintain their existing cytoreductive therapies, though questions remain about whether it will show the disease-modifying effects seen with ruxolitinib and interferons.
Latest:
Nivolumab/Relatlimab Shows Intracranial Activity in Melanoma Brain MetsNivolumab and relatlimab show promising intracranial activity in melanoma brain metastases, highlighting potential for further research in resistant cases.
Latest:
Olszewski Recaps Results of Mosunetuzumab in Elderly/Unfit DLBCLAdam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma.
Latest:
Emerging Therapies Are Explored in Low- and High-Risk MDSFor patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.
